Boehringer Ingelheim will start Phase III trials of leukemia drug in 2013

12 December 2012

Boehringer Ingelheim has chalked up another success for its oncology pipeline after revealing
positive Phase II trial results for acute myelogenous leukemia (AML) candidate volasertib.

The family-owned German drugmaker reported Phase II data from an ongoing open-label Phase I/II
trial of volasertib at the American Society of Hematology (ASH) meeting in Atlanta yesterday.

In the trial, volasertib was added to chemotherapy using low-dose cytarabine (LDAC), a standard
therapy for the 45% of AML patients who are ineligible for high-dose therapy aimed at inducing
remission in the cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK